WILKES NSG 552 EXAM 1 PSYCHOPHARMACOLOGY QUESTIONS
AND CORRECT ANSWERS (VERIFIED ANSWERS) PLUS
RATIONALES Q&A INSTANT DOWNLOAD PDF.
48 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Analyze the mechanistic basis of psychotropic drug action at receptor and transporter sites to predict
clinical and adverse effects
2 Apply pharmacokinetic and pharmacodynamic principles, including CYP450 interactions and
pharmacogenomic variation, to individualize psychotropic therapy
3 Synthesize evidence-based guidelines with patient-specific factors to select, monitor, and adjust
psychopharmacologic regimens safely
4 WILKES NSG 552 EXAM 1 PSYCHOPHARMACOLOGY QUESTIONS AND CORRECT ANSWERS
5 VERIFIED ANSWERS
6 PLUS RATIONALES Q&A INSTANT DOWNLOAD PDF.
7 Foundations of Psychopharmacology
8 Applied Psychopharmacology
9 Advanced Psychopharmacology
10 Psychopharmacology Review
ABSTRACT
This study document brings together 48 carefully worded exam questions drawn from WILKES
NSG 552 EXAM 1 PSYCHOPHARMACOLOGY QUESTIONS AND CORRECT ANSWERS
(VERIFIED ANSWERS) PLUS RATIONALES Q&A INSTANT DOWNLOAD PDF., with the
strongest emphasis placed on Analyze the mechanistic basis of psychotropic drug action at
receptor and transporter sites to predict clinical and adverse effects, Apply pharmacokinetic and
pharmacodynamic principles, including CYP450 interactions and pharmacogenomic variation, to
individualize psychotropic therapy, Synthesize evidence-based guidelines with patient-specific
factors to select, monitor and and adjust psychopharmacologic regimens safely. Every item follows
the wording style and level of reasoning you meet in the real paper, and each one is paired with a
clear rationale so the correct choice is never a guess. Work through the set at your own pace,
mark the questions that slow you down, then come back to them until the reasoning feels
automatic. Learners who revise this way walk into the exam room recognising the pattern behind
the questions instead of meeting them for the first time. Keep going - steady, honest practice is
what turns a difficult paper into a comfortable pass.
Page 1
,Q1 ANALYZE THE MECHANISTIC BASIS OF PSYCHOTROPIC DRUG ACTION AT RECEPTOR
AND TRANSPORTER SITES TO PREDICT CLINICAL AND ADVERSE EFFECTS
A patient stabilized on a standard SSRI develops intrusive thoughts after starting a
strong CYP2D6 inhibitor. Which mechanism best explains this pharmacokinetic
interaction?
A. Inhibition of CYP2D6 reduces parent drug clearance, increasing plasma SSRI concentrations
and serotonergic tone. CORRECT
B. CYP2D6 inhibition accelerates renal tubular secretion of the SSRI metabolite, lowering active
drug levels.
C. The inhibitor induces CYP3A4, shunting SSRI metabolism toward a neurotoxic metabolite.
D. Competition for the serotonin transporter increases synaptic serotonin independent of plasma
concentration.
RATIONALE: Most SSRIs are metabolized by CYP2D6; inhibiting this enzyme decreases
clearance and raises plasma levels, risking serotonergic toxicity. Options B and C misstate the
direction of metabolic effect, and D confuses pharmacodynamic transporter competition with a
pharmacokinetic interaction.
Q2 ANALYZE THE MECHANISTIC BASIS OF PSYCHOTROPIC DRUG ACTION AT RECEPTOR
AND TRANSPORTER SITES TO PREDICT CLINICAL AND ADVERSE EFFECTS
Which pharmacodynamic property most distinguishes atypical antipsychotics
from first-generation agents in producing minimal extrapyramidal symptoms at
therapeutic doses?
A. Higher affinity for D2 receptors with slow dissociation kinetics.
B. Rapid dissociation from D2 receptors combined with potent 5-HT2A antagonism. CORRECT
C. Selective blockade of D4 receptors in the mesolimbic pathway.
D. Irreversible inhibition of presynaptic dopamine autoreceptors.
RATIONALE: The 'fast-off-D2' hypothesis plus 5-HT2A antagonism allows transient D2 blockade
sufficient for antipsychotic effect but less sustained nigrostriatal blockade, reducing EPS. Slow
dissociation (A) and irreversible inhibition (D) would increase EPS risk, and D4 selectivity (C) is
not the established mechanism.
Page 2
, Q3 ANALYZE THE MECHANISTIC BASIS OF PSYCHOTROPIC DRUG ACTION AT RECEPTOR
AND TRANSPORTER SITES TO PREDICT CLINICAL AND ADVERSE EFFECTS
A patient on lithium develops coarse tremor, ataxia, and confusion. Which
additional finding would most strongly support lithium toxicity over a primary
neurologic disorder?
A. Serum lithium 1.4 mEq/L drawn 12 hours post-dose.
B. Serum lithium 2.1 mEq/L with elevated creatinine and decreased TSH. CORRECT
C. Serum lithium 0.8 mEq/L with normal renal function.
D. Serum lithium 1.1 mEq/L with leukocytosis.
RATIONALE: Levels >2.0 mEq/L with renal impairment and thyroid changes are classic for
lithium toxicity, which can occur even at lower levels with dehydration or interacting drugs. A and
D reflect therapeutic or borderline levels, and C is therapeutic with no toxicity evidence.
Q4 ANALYZE THE MECHANISTIC BASIS OF PSYCHOTROPIC DRUG ACTION AT RECEPTOR
AND TRANSPORTER SITES TO PREDICT CLINICAL AND ADVERSE EFFECTS
Which statement best explains why benzodiazepines with short elimination
half-lives are preferred for intermittent anxiety but carry higher interdose rebound
risk?
A. Rapid clearance produces steep plasma fluctuations, causing between-dose withdrawal
symptoms. CORRECT
B. Short half-life drugs have higher intrinsic efficacy at GABA-A receptors.
C. They accumulate active metabolites that prolong sedation.
D. They preferentially bind 1 subunits, producing less anxiolysis.
RATIONALE: Short half-life benzodiazepines cause rapid plasma level declines, leading to
interdose rebound anxiety or withdrawal. B confuses efficacy with kinetics, C describes
long-acting agents with active metabolites, and D misattributes subunit selectivity to half-life.
Page 3
AND CORRECT ANSWERS (VERIFIED ANSWERS) PLUS
RATIONALES Q&A INSTANT DOWNLOAD PDF.
48 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Analyze the mechanistic basis of psychotropic drug action at receptor and transporter sites to predict
clinical and adverse effects
2 Apply pharmacokinetic and pharmacodynamic principles, including CYP450 interactions and
pharmacogenomic variation, to individualize psychotropic therapy
3 Synthesize evidence-based guidelines with patient-specific factors to select, monitor, and adjust
psychopharmacologic regimens safely
4 WILKES NSG 552 EXAM 1 PSYCHOPHARMACOLOGY QUESTIONS AND CORRECT ANSWERS
5 VERIFIED ANSWERS
6 PLUS RATIONALES Q&A INSTANT DOWNLOAD PDF.
7 Foundations of Psychopharmacology
8 Applied Psychopharmacology
9 Advanced Psychopharmacology
10 Psychopharmacology Review
ABSTRACT
This study document brings together 48 carefully worded exam questions drawn from WILKES
NSG 552 EXAM 1 PSYCHOPHARMACOLOGY QUESTIONS AND CORRECT ANSWERS
(VERIFIED ANSWERS) PLUS RATIONALES Q&A INSTANT DOWNLOAD PDF., with the
strongest emphasis placed on Analyze the mechanistic basis of psychotropic drug action at
receptor and transporter sites to predict clinical and adverse effects, Apply pharmacokinetic and
pharmacodynamic principles, including CYP450 interactions and pharmacogenomic variation, to
individualize psychotropic therapy, Synthesize evidence-based guidelines with patient-specific
factors to select, monitor and and adjust psychopharmacologic regimens safely. Every item follows
the wording style and level of reasoning you meet in the real paper, and each one is paired with a
clear rationale so the correct choice is never a guess. Work through the set at your own pace,
mark the questions that slow you down, then come back to them until the reasoning feels
automatic. Learners who revise this way walk into the exam room recognising the pattern behind
the questions instead of meeting them for the first time. Keep going - steady, honest practice is
what turns a difficult paper into a comfortable pass.
Page 1
,Q1 ANALYZE THE MECHANISTIC BASIS OF PSYCHOTROPIC DRUG ACTION AT RECEPTOR
AND TRANSPORTER SITES TO PREDICT CLINICAL AND ADVERSE EFFECTS
A patient stabilized on a standard SSRI develops intrusive thoughts after starting a
strong CYP2D6 inhibitor. Which mechanism best explains this pharmacokinetic
interaction?
A. Inhibition of CYP2D6 reduces parent drug clearance, increasing plasma SSRI concentrations
and serotonergic tone. CORRECT
B. CYP2D6 inhibition accelerates renal tubular secretion of the SSRI metabolite, lowering active
drug levels.
C. The inhibitor induces CYP3A4, shunting SSRI metabolism toward a neurotoxic metabolite.
D. Competition for the serotonin transporter increases synaptic serotonin independent of plasma
concentration.
RATIONALE: Most SSRIs are metabolized by CYP2D6; inhibiting this enzyme decreases
clearance and raises plasma levels, risking serotonergic toxicity. Options B and C misstate the
direction of metabolic effect, and D confuses pharmacodynamic transporter competition with a
pharmacokinetic interaction.
Q2 ANALYZE THE MECHANISTIC BASIS OF PSYCHOTROPIC DRUG ACTION AT RECEPTOR
AND TRANSPORTER SITES TO PREDICT CLINICAL AND ADVERSE EFFECTS
Which pharmacodynamic property most distinguishes atypical antipsychotics
from first-generation agents in producing minimal extrapyramidal symptoms at
therapeutic doses?
A. Higher affinity for D2 receptors with slow dissociation kinetics.
B. Rapid dissociation from D2 receptors combined with potent 5-HT2A antagonism. CORRECT
C. Selective blockade of D4 receptors in the mesolimbic pathway.
D. Irreversible inhibition of presynaptic dopamine autoreceptors.
RATIONALE: The 'fast-off-D2' hypothesis plus 5-HT2A antagonism allows transient D2 blockade
sufficient for antipsychotic effect but less sustained nigrostriatal blockade, reducing EPS. Slow
dissociation (A) and irreversible inhibition (D) would increase EPS risk, and D4 selectivity (C) is
not the established mechanism.
Page 2
, Q3 ANALYZE THE MECHANISTIC BASIS OF PSYCHOTROPIC DRUG ACTION AT RECEPTOR
AND TRANSPORTER SITES TO PREDICT CLINICAL AND ADVERSE EFFECTS
A patient on lithium develops coarse tremor, ataxia, and confusion. Which
additional finding would most strongly support lithium toxicity over a primary
neurologic disorder?
A. Serum lithium 1.4 mEq/L drawn 12 hours post-dose.
B. Serum lithium 2.1 mEq/L with elevated creatinine and decreased TSH. CORRECT
C. Serum lithium 0.8 mEq/L with normal renal function.
D. Serum lithium 1.1 mEq/L with leukocytosis.
RATIONALE: Levels >2.0 mEq/L with renal impairment and thyroid changes are classic for
lithium toxicity, which can occur even at lower levels with dehydration or interacting drugs. A and
D reflect therapeutic or borderline levels, and C is therapeutic with no toxicity evidence.
Q4 ANALYZE THE MECHANISTIC BASIS OF PSYCHOTROPIC DRUG ACTION AT RECEPTOR
AND TRANSPORTER SITES TO PREDICT CLINICAL AND ADVERSE EFFECTS
Which statement best explains why benzodiazepines with short elimination
half-lives are preferred for intermittent anxiety but carry higher interdose rebound
risk?
A. Rapid clearance produces steep plasma fluctuations, causing between-dose withdrawal
symptoms. CORRECT
B. Short half-life drugs have higher intrinsic efficacy at GABA-A receptors.
C. They accumulate active metabolites that prolong sedation.
D. They preferentially bind 1 subunits, producing less anxiolysis.
RATIONALE: Short half-life benzodiazepines cause rapid plasma level declines, leading to
interdose rebound anxiety or withdrawal. B confuses efficacy with kinetics, C describes
long-acting agents with active metabolites, and D misattributes subunit selectivity to half-life.
Page 3
